Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes

Journal of Invasive Cardiology

Volumn 12, Issue SUPPL. E, 2000, Pages

  Cohen, Marc ^a,b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HAHNEMANN UNIVERSITY HOSPITAL   (United States)

Author keywords

Enoxaparin; Low molecular weight heparin; Non ST segment elevation acute coronary syndromes; Platelet aggregation; Tirofiban

Indexed keywords

DRUG DERIVATIVE; ENOXAPARIN; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; TIROFIBAN; TYROSINE;

ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; ELECTROCARDIOGRAPHY; EVALUATION; FEMALE; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SAFETY; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SAFETY; TYROSINE;

EID: 0034566824     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cohen M, Adams PC, Parry G, et al. and the Antithrombotic Therapy in Acute Coronary Syndromes research group. Combination anti-thrombotic therapy in unstable rest angina and non-Q wave infarction in nonprior aspirin users: Primary endpoints analysis from the ATACS trial. Circulation 1994;89:81-88.
2. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568.
3. Cohen M, Demers C, Gurfinkel EP, et al., for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events study group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-452.
4. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100:1593-1601.
5. Antman EM, Cohen M, Radley D, et al. for the TIMI 11B and ESSENCE investigators. Enoxaparin for unstable angina/non-Q wave myocardial infarction: Meta-analysis of TIMI 11B and ESSENCE. Circulation 1999;100:1602-1608.
6. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
7. The PRISM investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-1505.
8. The PRISM-PLUS investigators. Inhibition of the glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998;338:1488-1497.
9. The PURSUIT Trial investigators. Inhibition of glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443.
10. Farhi JI, Cohen M, Fuster V. The broad spectrum of unstable angina pcctoris and its implications for future controlled trials. Am J Cardiol 1986;58:547-550.
11. Cohen M, Stinnett SS, Weatherley B, et al. for the ESSENCE study group. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. Am Heart J 2000; 139:962-970.
12. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000;284:835-842.
13. Salzman EW, Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980;65:64-73.
14. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-256.
15. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-698.
16. Deckelbaum LI, Sax FL, Grossman W. Tirofiban, a nonpeptide inhibitor of the glycoprotein IIb/IIIa receptor. New Therapeutic Agents in Thrombosis and Thrombolysis. Marcel Dekker, Inc., 1997.
17. Cohen M, Theroux P, Weber S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999;71:273-281.
18. Kereiakes DJ, Broderick TM, Roth EM, et al. Am J Cardiol 1999;84:391-395.
19. Kereiakes DJ, Fry E, Matthai W, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first." J Invas Cardiol 2000;12(Suppl A):1A-5A.
20. Merck sponsored clinical trial: "A multicenter, randomized, controlled, double-blind trial to investigate the clinical efficacy and tolerability of early treatment with Simvastatin 40 mg daily for 30 days, followed by Simvastatin 80 mg daily thereafter in tirofiban treated acute coronary syndrome patients who have been randomized to receive enoxaparin or unfractionated heparin in conjunction with aspirin. Principal Investigator: Eugene Braunwald, MD.
21. Cohen M, Maritz F, Gensini GF, et al. The TETAMI trial: The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and of tirofiban versus placebo in the treatment of acute myocardial infarction for patients not thrombolysed; Methods and Design. J Thromb Thrombolysis (in press).
22. Cohen M, Theroux P, White HD, et al. Anti-thrombotic combination using tirofiban and enoxaparin: The ACUTE II study. Circulation 2000;102(Suppl II):II-826.